Epigenetic Reprogramming in Relapse/Refractory AML
Phase 1 Completed
37 enrolled 11 charts
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Phase 1 Completed
65 enrolled 38 charts
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Phase 1 Completed
25 enrolled
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
Phase 1 Completed
21 enrolled
BMT-03
Phase 1 Completed
12 enrolled 12 charts
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Phase 1 Completed
150 enrolled 9 charts
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
BMS-247550 in Treating Patients With Cancers That Have Not Responded to Previous Therapy
Phase 1 Completed
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Phase 1 Completed
18 enrolled
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Phase 1 Completed
12 enrolled 13 charts
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
Phase 1 Completed
15 enrolled
BSO
Phase 1 Completed
31 enrolled
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
Phase 1 Completed
27 enrolled
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Phase 1 Completed
83 enrolled
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 1 Completed
11 enrolled
Cabozantinib With Topotecan-Cyclophosphamide
Phase 1 Completed
12 enrolled
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Phase 1 Completed
32 enrolled 12 charts
Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Completed
30 enrolled
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
Phase 1 Completed
43 enrolled
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Phase 1 Completed
5 enrolled
A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1 Completed
55 enrolled
A Study of ARRY-520 in Patients With Advanced Cancer
Phase 1 Completed
41 enrolled
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Phase 1 Completed
55 enrolled
Docetaxel and Epirubicin With and Without G-CSF in Treating Women With Metastatic Breast Cancer
Phase 1 Completed
50 enrolled
Cord Blood Expansion on Mesenchymal Stem Cells
Phase 1 Completed
98 enrolled
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
Phase 1 Completed
21 enrolled
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
Phase 1 Completed
34 enrolled
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
Phase 1 Completed
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Phase 1 Completed
28 enrolled
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Phase 1 Completed
48 enrolled
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
29 enrolled
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer
Phase 1 Completed
23 enrolled
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 1 Completed
74 enrolled
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Phase 1 Completed
10 enrolled
A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas
Phase 1 Completed
8 enrolled
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
Phase 1 Completed
27 enrolled
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
Phase 1 Completed
33 enrolled
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Phase 1 Completed
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
25 enrolled
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
Phase 1 Completed
78 enrolled
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Phase 1 Completed
25 enrolled
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Phase 1 Completed
33 enrolled
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Completed
15 enrolled
Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast Cancer
Phase 1 Completed
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Phase 1 Completed
10 enrolled
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
8 enrolled
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Completed
35 enrolled
Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
Phase 1 Completed
20 enrolled
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Phase 1 Completed
16 enrolled
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Phase 1 Completed
24 enrolled 9 charts